Advances in the treatment of chronic myeloid leukemia
Author Information
Author(s): Anna M Eiring, Jamshid S Khorashad, Kimberly Morley, Michael W Deininger
Primary Institution: University of Utah Huntsman Cancer Institute
Conclusion
The treatment landscape for chronic myeloid leukemia has improved significantly with the introduction of second generation tyrosine kinase inhibitors, although challenges remain for patients with resistant disease.
Supporting Evidence
- Imatinib has been a breakthrough treatment for chronic myeloid leukemia, but newer drugs like dasatinib and nilotinib show promise for better outcomes.
- Patients with the T315I mutation have effective treatment options like ponatinib that are nearing regulatory approval.
- Stopping therapy remains a topic of clinical trials, with some patients able to maintain remission without ongoing treatment.
Takeaway
Doctors are finding better ways to treat a type of blood cancer called chronic myeloid leukemia, but some patients still have problems with their treatment not working.
Methodology
This minireview discusses recent advancements in therapies for chronic myeloid leukemia, including second generation tyrosine kinase inhibitors and strategies for treatment discontinuation.
Potential Biases
There is a risk of bias due to the reliance on data from clinical trials that may not fully represent real-world patient experiences.
Limitations
The review highlights that many patients may not adhere to treatment, which can lead to poor outcomes, and that the effectiveness of new therapies may vary in community settings.
Participant Demographics
The median age at diagnosis is 60 years, and the review discusses various patient responses based on risk scores.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website